Notal Vision
Notal Vision is a privately held digital health company offering FDA-authorized, patient-operated remote monitoring devices (ForeseeHome and SCANLY Home OCT) with proprietary AI-based OCT analysis for the early detection and management of age-related macular degeneration, delivered to retina specialists and patients in the United States.
- Company typePrivate
- Founded2012
- HeadquartersManassas, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Notal Vision does
Notal Vision is a privately held digital health company that delivers remote patient monitoring services for retinal diseases, extending ophthalmic disease management from the clinic to the home. The company's commercial platform centers on two FDA-authorized patient-operated devices — ForeseeHome, which uses patented Preferential Hyperacuity Perimetry (PHP) for early detection of wet AMD conversion in intermediate dry AMD patients, and SCANLY Home OCT, an AI-powered spectral-domain optical coherence tomography device authorized via De Novo in May 2024 for monitoring disease activity in neovascular AMD. Imaging data is wirelessly transmitted to the Notal Health Cloud, where the proprietary Notal OCT Analyzer (NOA) performs automated detection and segmentation of retinal hypo-reflective spaces, generating annotated B-scans, en-face projections, and volume trajectories for physician review.
The company operates through a physician-prescribed model in which retina specialists order the devices, and the Notal Vision Monitoring Center — a Medicare-recognized Independent Diagnostic Testing Facility (IDTF) — manages patient enrollment, benefit verification, device fulfillment, billing, and 24/7 clinical data monitoring via a HIPAA-compliant portal. Reimbursement is secured under established Medicare coverage (ForeseeHome since 2015) and CPT codes 0604T, 0605T, and 0606T for SCANLY remote OCT analysis on a monthly cadence, with the company actively expanding coverage with Medicare Administrative Contractors. Headquartered in Manassas, Virginia, with R&D in Tel Aviv, Israel, Notal Vision is backed by Ganot Capital, Soleus Capital, Elron Ventures, and Evergreen Venture Partners, and has raised approximately $85 million across funding rounds in 2019 and 2021. The pipeline extends the Home OCT and NOA platform to diabetic macular edema (DME) and retinal vein occlusion (RVO).
Notal Vision firmographics
Firmographics- Name
- Notal Vision
- Legal name
- Notal Vision, Inc.
- Website
- https://notalvision.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Notal Vision is a privately held digital health company offering FDA-authorized, patient-operated remote monitoring devices (ForeseeHome and SCANLY Home OCT) with proprietary AI-based OCT analysis for the early detection and management of age-related macular degeneration, delivered to retina specialists and patients in the United States.
- Ownership category
- akta.pro rank
Notal Vision industry classification
Industry- Product category
- Ophthalmic Remote Patient Monitoring
- NAICS
- Diagnostic Imaging Centers (621512), Ambulatory Health Care Services (621)
- SIC
- Services-Medical Laboratories (8071), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
- akta.pro secondary industries
- Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC), Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)
Keywords
Where Notal Vision is headquartered
LocationHeadquarters
- HQ city
- Manassas
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Notal Vision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Remote Monitoring Services: The Notal Vision Monitoring Center bills patients or their insurance (including Medicare) for the SCANLY Home OCT Monitoring Program using established CPT codes (0604T, 0605T, 0606T) for remote OCT analysis every 30 days. ForeseeHome technical component is covered by Medicare for qualifying dry AMD patients.
- ForeseeHome Monitoring Program: The ForeseeHome AMD Monitoring Program is covered by Medicare and most private insurance. The technical component is billed to Medicare subject to coverage requirements for testing dry AMD patients at risk of developing wet AMD.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Monthly | SCANLY Home OCT Monitoring Program - Physician-directed remote monitoring for wet AMD patients |
| Subscription | Monthly | ForeseeHome AMD Monitoring Program - Medicare-covered home monitoring for intermediate dry AMD |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Notal Vision product offering
Product offeringCore offering
Notal Vision provides home-based remote patient monitoring services for retinal diseases, primarily age-related macular degeneration. The company offers two FDA-authorized patient-operated diagnostic devices—ForeseeHome (PHP-based metamorphopsia testing for dry AMD) and SCANLY Home OCT (AI-powered spectral-domain OCT for wet AMD)—supported by the proprietary Notal OCT Analyzer (NOA) and the Notal Vision Monitoring Center, a Medicare-recognized IDTF that delivers 24/7 connectivity, automated analysis, and physician alerts.
Product overview
Notal Vision is a digital health company offering a platform of remote patient monitoring services for retinal diseases, extending eye disease management from clinic to home. The core portfolio includes ForeseeHome® (FDA-cleared PHP-based home monitoring for dry AMD patients at risk of wet AMD conversion) and SCANLY® Home OCT (FDA-authorized AI-powered home OCT for wet AMD patients). Both products are supported by the Notal Vision Monitoring Center, a Medicare-recognized IDTF providing comprehensive patient engagement, clinical data monitoring, and physician portal services. The proprietary Notal OCT Analyzer (NOA) provides AI-based automated analysis of OCT images for the SCANLY system. Pipeline programs include Home OCT and NOA expansions for diabetic macular edema (DME) and retinal vein occlusion (RVO).
Differentiator
Problem solved
Functional benefit
Brands
- ForeseeHome: FDA-cleared home-based monitoring program for early detection of wet AMD in intermediate dry AMD patients using Preferential Hyperacuity Perimetry technology.
- SCANLY
Products and services
- ForeseeHome® FDA-cleared home-based monitoring device using Preferential Hyperacuity Perimetry (PHP) technology for early detection of wet AMD in patients with intermediate dry age-related macular degeneration. Patient-operated; alerts physicians to potential disease activity between scheduled clinic visits.
- SCANLY® Home OCT FDA-authorized AI-powered home optical coherence tomography system for patients with neovascular AMD. Patient self-operated device captures spectral-domain OCT images in a 10x10 degree macular area, with images automatically transmitted to the Notal Health Cloud for AI analysis and physician review via a HIPAA-compliant web portal.
- Notal Vision Monitoring Center Medicare-recognized Independent Diagnostic Testing Facility providing 24/7 patient-physician connectivity, automated alert management, HIPAA-compliant web portal access, device management, clinical data monitoring, billing services, and patient engagement for the ForeseeHome and SCANLY programs.
Quantifiable outcome
- Only 34% of eyes retain driving vision at wet AMD diagnosis in standard care
- +3 more outcomes
Companies that use Notal Vision
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles2 records
Notal Vision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
Notal Vision partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Wasatch PhotonicscorePartnership announced December 2018 to bring AI-enabled home-based Optical Coherence Tomography closer to market. Wasatch Photonics provides optical technology expertise for the home OCT device.
- Cleveland CliniccoreResearch partnership for AMD monitoring and detection studies. One of the world's leading academic medical centers specializing in ophthalmology research.
- Queens University BelfastcoreResearch partnership in ophthalmic imaging and analysis. Collaborates on clinical studies for AMD home monitoring technology.
- Tel Aviv Medical CentercoreResearch partnership with Dr. Anat Loewenstein's Department of Ophthalmology. Key international opinion leader in vitreoretinal disease research.
- Singapore National Eye CentreminorResearch partnership for AMD monitoring technology. Leading eye care center in Asia Pacific region.
- MDA (Macular Degeneration Association)minorAssociation partnership to raise awareness of AMD home monitoring and support patient education.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Notal Vision competitors and assessment
Company assessmentRegional players
- Airdoc: China-based AI retinal imaging company with multiple regulatory clearances for AI-based screening using fundus photography. Comparable as an AI-driven ophthalmic diagnostics company pursuing hardware-plus-software screening and monitoring models.
Direct peers
- Optomed: Maker of handheld fundus cameras and AI-enabled screening solutions deployed at primary care and screening sites. Comparable as a vendor of patient-/operator-friendly ophthalmic imaging hardware with AI-based diagnostic software.
- Heidelberg Engineering: Manufacturer of SPECTRALIS OCT systems and other ophthalmic diagnostic devices. Closely comparable as an OCT hardware specialist serving retina specialists, and the prior employer of Notal's CEO. Competes for the same clinical workflow today and could extend into home OCT.
- iCare (including former CenterVue): Provides a portfolio of ophthalmic diagnostic devices including OCT and home/portable tonometers. Comparable as a developer of clinician- and patient-operated ophthalmic diagnostics with similar reimbursement and specialty-channel go-to-market.
Emerging players
- Eyenuk: Developer of EyeArt, an FDA-cleared AI system for autonomous detection of diabetic retinopathy from retinal images. Comparable as an AI-enabled ophthalmic diagnostics company leveraging retinal imaging for screening and monitoring.
- Remidio Innovative Solutions: Develops smartphone-based retinal imaging systems with AI screening for diabetic retinopathy and AMD. Comparable as a disruptor using AI on lower-cost retinal imaging hardware to extend eye-care diagnostics beyond specialty clinics.
- Digital Diagnostics (IDx): Pioneer of autonomous AI diagnostic systems, including IDx-DR for diabetic retinopathy. Comparable as a company bringing FDA-authorized, AI-enabled ophthalmic diagnostics to non-specialist care settings.
Broad incumbents
- Carl Zeiss Meditec: Global leader in ophthalmic devices including CIRRUS OCT and integrated diagnostic platforms. Comparable as a large incumbent with the clinical relationships and capital to compete across ophthalmic imaging, including home-based extensions.
- Nidek: Japanese manufacturer of ophthalmic diagnostic equipment including OCT and fundus cameras with global distribution. Comparable as an incumbent OCT/OCT angiography vendor whose installed base could be leveraged to compete in remote monitoring.
- Topcon Healthcare: Major ophthalmic imaging and diagnostic equipment manufacturer with a broad portfolio including OCT, fundus cameras, and screening solutions. Comparable as an incumbent that could expand its OCT platform into home or remote monitoring.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Notal Vision social profiles
Digital presenceNotal Vision compliance and trust
Trust signalCompliance3 records
Notal Vision financial estimates
Financial estimateRevenue estimate
Valuation estimate
Notal Vision leadership team
Management profileNumber of profiles
Profiles8 records
Notal Vision funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Notal Vision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Notal Vision
What does Notal Vision do?
Notal Vision provides home-based remote patient monitoring services for retinal diseases, primarily age-related macular degeneration. The company offers two FDA-authorized patient-operated diagnostic devices—ForeseeHome (PHP-based metamorphopsia testing for dry AMD) and SCANLY Home OCT (AI-powered spectral-domain OCT for wet AMD)—supported by the proprietary Notal OCT Analyzer (NOA) and the Notal Vision Monitoring Center, a Medicare-recognized IDTF that delivers 24/7 connectivity, automated analysis, and physician alerts.
Is Notal Vision a public or private company?
Notal Vision is a private company. It is classified as venture growth investor backed and is currently operating.
When was Notal Vision founded?
Notal Vision was founded in 2012. It employs 51 to 100 people.
Where is Notal Vision based?
Notal Vision is headquartered in Manassas, United States, in the North America region.
How does Notal Vision make money?
Two revenue lines are on record. Remote Monitoring Services are the primary driver. The others are foreseeHome Monitoring Program.
Who are Notal Vision's main competitors?
Airdoc is listed as a regional player. Direct peers are Optomed, Heidelberg Engineering and iCare (including former CenterVue). Emerging players are Eyenuk, Remidio Innovative Solutions and Digital Diagnostics (IDx). Broad incumbents are Carl Zeiss Meditec, Nidek and Topcon Healthcare.
Does Notal Vision have an API?
No public API is recorded for Notal Vision.
What industry is Notal Vision in?
Notal Vision's product category is Ophthalmic Remote Patient Monitoring. Its primary akta.pro industry code is HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers), with a secondary code of HLAHAJAC, Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity). Its NAICS code is 621512 and its SIC code is 8071.